Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in 91色情片) to develop its malaria
vaccine. GSK鈥檚 vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials鈥攖he best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas 鈥渁t a very reasonable price鈥.
More from New Scientist
Explore the latest news, articles and features
Technology
Test moderators use AI-generated writing to judge literacy standards
News
Mind
THC in cannabis may reduce nightmares in people with PTSD
News
Environment
Fishers detonate a bomb every hour on one Indonesian coral reef
News
Environment
How bad is the UK drought and how long will it continue?
News
Popular articles
Trending New Scientist articles